Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

Recent advancements in imaging techniques and the use of neoadjuvant chemotherapy (NCT) are reshaping how colon cancer is diagnosed and treated. Neoadjuvant chemotherapy refers to the ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

although this will be partially offset if the test Results diminish the proportion of stage II patients deemed to require adjuvant chemotherapy.

With minimal blood loss and scarring, and faster recovery period, robotic surgeries are becoming game changers in the ...

In a nutshell A common desert plant called Artemisia herba-alba contains compounds that can effectively kill colorectal ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

Adjuvant chemotherapy is now considered the standard treatment for stage III colon cancer, and has evolved recently with the introduction of infusional, combination chemotherapy. Adjuvant therapy ...

More information: Scott Kopetz et al, Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial, Nature Medicine (2025). DOI: 10.1038/s41591-024-03443-3 ...